Volltext-Downloads (blau) und Frontdoor-Views (grau)

Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best among the Bad?

  • Osteoporosis is a chronical, systemic skeletal disorder characterized by an increase in bone resorption, which leads to reduced bone density. The reduction in bone mineral density and therefore low bone mass results in an increased risk of fractures. Osteoporosis is caused by an imbalance in the normally strictly regulated bone homeostasis. This imbalance is caused by overactive bone-resorbing osteoclasts, while bone-synthesizing osteoblasts do not compensate for this. In this review, the mechanism is presented, underlined by in vitro and animal models to investigate this imbalance as well as the current status of clinical trials. Furthermore, new therapeutic strategies for osteoporosis are presented, such as anabolic treatments and catabolic treatments and treatments using biomaterials and biomolecules. Another focus is on new combination therapies with multiple drugs which are currently considered more beneficial for the treatment of osteoporosis than monotherapies. Taken together, this review starts with an overview and ends with the newest approaches for osteoporosis therapies and a future perspective not presented so far.

Download full text files

Export metadata

Additional Services

Search Google Scholar Check availability


Show usage statistics
Document Type:Article
Author:Christian Horst Tonk, Sarah Hani Shoushrah, Patrick Babczyk, Basma El Khaldi-Hansen, Margit Schulze, Monika Herten, Edda Tobiasch
Parent Title (English):International Journal of Molecular Sciences
Article Number:1393
Number of pages:36
Place of publication:Basel
Publishing Institution:Hochschule Bonn-Rhein-Sieg
Date of first publication:2022/01/26
Copyright:© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Funding:This work was supported by the Bundesministerium für Bildung und Forschung (BMBF) FHprofUnt to E.T., FKZ: 13FH012PB2; Bundesministerium für Bildung und Forschung (BMBF) IngenieurNachwuchs to E.T., FKZ: 03FH019IX5; Ministerium für Innovation, Wissenschaft und Forschung (MIWF) NRW FH Zeit für Forschung to E.T., FKZ 005-1703-0017. Bundesministerium für Bildung und Forschung (BMBF) IngenieurNachwuchs to S.W., FKZ: 13FH569IX6. A PhD scholarship was given by the graduate institute (GI) of the Bonn-Rhein-Sieg University of Applied Sciences to B.E.K.-H. and S.H.S.
Keyword:Treatment; anabolic; biomaterial; bone mineral density; bone remodeling; catabolic; combination of treatments; osteoblast; osteoclast; osteoporosis
Departments, institutes and facilities:Fachbereich Angewandte Naturwissenschaften
Projects:IngenieurNachwuchs 2015: PersoImplant - Personalisierte zellbesiedelte Implantate für Knochendefekte mit 'kritischer Größe' (DE/BMBF/03FH019IX5,13FH019IX5)
IngenieurNachwuchs 2016: Hybrid-KEM - Entwicklung neuer Hybride auf Phosphat/Silicat/Agarose-Basis als KnochenErsatzMaterial mit Release-Funktion für Bisphosphonat-Wirkstoffe (DE/BMBF/13FH569IX6)
MeMoAthero - FHprofUnt2012: Mechanismus und Modell der Atherosklerose: Entwicklung eines Medikamententestsystems für einen neuartigen Behandlungsansatz (DE/BMBF/03FH012PB2,13FH012PB2)
Dewey Decimal Classification (DDC):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Open access funding:Hochschule Bonn-Rhein-Sieg / Graduierteninstitut
Entry in this database:2022/02/16
Licence (German):License LogoCreative Commons - CC BY - Namensnennung 4.0 International